Thalidomide

Generic Name
Thalidomide
Brand Names
Thalomid, Thalidomide BMS (previously Thalidomide Celgene), Thalidomide Lipomed
Drug Type
Small Molecule
Chemical Formula
C13H10N2O4
CAS Number
50-35-1
Unique Ingredient Identifier
4Z8R6ORS6L
Background

A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence.

Indication

Thalidomide is primarily used for the acute treatment and maintenance therapy to prevent and suppress the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL).

Associated Conditions
Aphthous Stomatitis, Chronic Graft-Versus-Host Disease, Erythema Nodosum Leprosum, Multiple Myeloma (MM), Primary Amyloidosis, Uremic Pruritus, Waldenström's Macroglobulinemia (WM), Moderate Erythema nodosum leprosum, Refractory Graft versus host disease, Severe Erythema nodosum leprosum, Treatment naive multiple myeloma
Associated Therapies
-
Clinical Trials
Related News

Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma

First Posted Date
2012-02-23
Last Posted Date
2015-01-26
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
7
Registration Number
NCT01537861
Locations
🇺🇸

Washington University School of Medicine, St. Louis, Missouri, United States

Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM

First Posted Date
2012-02-06
Last Posted Date
2018-07-03
Lead Sponsor
Azienda Ospedaliera di Bolzano
Target Recruit Count
30
Registration Number
NCT01526694
Locations
🇮🇹

AULSS 2 Feltre, Feltre, Italy

🇮🇹

Ospedale Ca Foncello, Treviso, Italy

🇮🇹

Ospedale dell'Angelo di Mestre, Mestre, Italy

and more 16 locations

Efficacy of Thalidomide in the Treatment of Hereditary Hemorrhagic Telangiectasia

First Posted Date
2011-12-05
Last Posted Date
2017-08-29
Lead Sponsor
Fondazione IRCCS Policlinico San Matteo di Pavia
Target Recruit Count
31
Registration Number
NCT01485224
Locations
🇮🇹

Clinica Medica 3, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy

Antiangiogenic Therapy for Children with Recurrent Medulloblastoma, Ependymoma and ATRT

First Posted Date
2011-05-19
Last Posted Date
2024-10-21
Lead Sponsor
Medical University of Vienna
Target Recruit Count
100
Registration Number
NCT01356290
Locations
🇺🇸

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

🇺🇸

Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts, United States

🇺🇸

Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States

and more 19 locations

THAL-DEX Incorporated Into Double PBSC Autotransplantation for Untreated Multiple Myeloma (MM)

Phase 2
Completed
Conditions
Multiple Myeloma
First Posted Date
2011-04-25
Last Posted Date
2011-04-25
Lead Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Target Recruit Count
378
Registration Number
NCT01341262

VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)

First Posted Date
2010-06-02
Last Posted Date
2012-07-20
Lead Sponsor
Michele Cavo
Target Recruit Count
480
Registration Number
NCT01134484
Locations
🇮🇹

AOU di Bologna Policlinico S.Orsola-Malpighi, UO di Ematologia, Bologna, Italy

Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL

First Posted Date
2010-05-18
Last Posted Date
2022-01-21
Lead Sponsor
Weill Medical College of Cornell University
Target Recruit Count
15
Registration Number
NCT01125176
Locations
🇺🇸

Weill Cornell Medical College, New York, New York, United States

Thalidomide for Patients With Mild to Moderate Alzheimer's Disease

Phase 2
Conditions
Alzheimer's Disease
Interventions
Drug: Thalidomide
First Posted Date
2010-03-26
Last Posted Date
2012-08-08
Lead Sponsor
Banner Health
Target Recruit Count
20
Registration Number
NCT01094340
Locations
🇺🇸

Banner Sun Health Research Institute, Sun City, Arizona, United States

Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma

First Posted Date
2010-01-27
Last Posted Date
2017-12-12
Lead Sponsor
Mayo Clinic
Target Recruit Count
64
Registration Number
NCT01057225
Locations
🇺🇸

Mayo Clinic in Arizona, Scottsdale, Arizona, United States

🇺🇸

Medical University of South Carolina, Charleston, South Carolina, United States

🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

First Posted Date
2010-01-25
Last Posted Date
2015-03-06
Lead Sponsor
SWOG Cancer Research Network
Registration Number
NCT01055301
Locations
🇺🇸

Harborview Medical Center, Seattle, Washington, United States

🇺🇸

Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

🇺🇸

Group Health Central Hospital, Seattle, Washington, United States

and more 18 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy